KCL-440

• UNSPSC Description:

  KCL-440 is a CNS-penetrated PARP inhibitor, with an IC50 of 68 nM. KCL-440 has strong inhibition of PARP-1[1][2].

• Target Antigen:

  PARP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/kcl-440.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1NC=C(C2=CC=C(CN(C)C)C=C2)C3=C(O)C=CC=C31

• Molecular Weight:

  294.35

• References & Citations:

  [1]Yasuhiko Ikeda, et al. Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model. Brain Res. 2005 Oct 26;1060(1-2):73-80.|[2]Tatsushi Kamiya, et al. The neuroprotective effects of a newly synthesized poly (ADP-ribose) polymerase (PARP) inhibitor (KCL-440) on neuronal cell death following transient focal ischemia in rat. Journal of Cerebral Blood Flow & Metabolism. 2005.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  651029-09-3